Impact Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 10, 2020

Primary Completion Date

December 12, 2020

Study Completion Date

December 21, 2020

Conditions
Central Nervous System Diseases
Interventions
DRUG

Dexmedetomidine

Dexmedetomidine hydrochloride (200 μg/2 ml) is diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour (dexmedetomidine 0.1 μg/kg/hour). The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.

DRUG

Normal saline group

Normal saline is also diluted with normal saline to 50 ml and is continuously intravenous infused at a rate of 0.025 ml/kg/hour, which is the same with the dexmedetomidine group. The intravenous infusion begins immediately after enrollment until 08:00 AM on the postoperative day one.

Trial Locations (1)

100050

ICU, Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Capital Medical University

OTHER

NCT04494828 - Impact Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor | Biotech Hunter | Biotech Hunter